|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
Altor has developed a unique proprietary technology for producing biologically active, soluble TCR molecules in a single-chain format. The resulting STAR™ molecules retain the ability of the TCR to specifically recognize novel targets on virus-infected or cancerous cells, including intracellular antigens that are not accessible to therapeutic antibodies. Altor has developed STAR™ fusions with cytokines and antibody-like STAR™ fusions which function as therapeutics. STAR™ fusions are ideally suited to deliver anti-cancer and anti-viral drugs, such as approved immunomodulatory cytokines, cytotoxic drugs, radioisotopes, and imaging agents, directly to diseased cells and tissues. Altor’s drug development strategy is to employ the unique antigen recognition properties of the TCR to lower the therapeutic dosage of currently approved drugs and decrease their side effects while maintaining their efficacy. Altor will adopt the proven clinical path of these approved drugs for development of STAR™-based therapeutics to maximize their chances of success in the clinic.
|
Altor Bioscience Corporation Email Formats | Example Email Formats | Percentage |
---|---|---|
{first}{last} | [email protected] |
100%
|
The widely used Altor Bioscience Corporation email format is {first}{last} (e.g. [email protected]) with 100% adoption across the company.
To contact Altor Bioscience Corporation customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.